Clinical trials: Anticoagulants
New Onset Atrial Fibrillation
Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring
This pilot study aims to assess the feasibility and safety of using an ILR to identify the incidence of recurrent AF after an episode of newly diagnosed AF.
- Trial name
- NCT04038944
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- St. Francis Hospital, New York
Venous Thromboembolism, Thromboembolism
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Conditions
- Venous Thromboembolism, Thromboembolism, Thrombosis, Embolism and Thrombosis
- Trial name
- NCT01203098
- Testing
- DU-176b 15mg, DU-176b 30mg, Enoxaparin sodium 20 mg (=2000IU)
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 264 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Recurrent Venous Thromboembolism, Idiopathic Deep Vein Thrombosis
Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)
In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of…
- Trial name
- PADIS TVP (NCT00740493)
- Testing
- warfarin
- Where
- 14 sites in France
- Volunteers
- 104 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
The Effectiveness of Interactive Nursing Education Program Through Health Belief Model Based and Informative Technology-assisted on Atrial Fibrillation Patients Receiving Oral Anticoagulant
This study examined patients on taking oral anticoagulants (OACs) are often prescribed for Atrial fibrillation (AFib) to determine the effectiveness of a multiple interactive health education program, which was developed based on…
- Trial name
- NCT05145634
- Testing
- Patient education related oral anticoagulants (OACs)
- Volunteers
- 150 people
- Sponsor
- Chang Gung Memorial Hospital
Pneumonia, Viral
Steroid and Anticoagulant Therapy in covid19
As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients.
- Trial name
- SARS-CoV-2 (NCT05021588)
- Testing
- steroid and anticoagulants according to different protocols.
- Where
- Egypt
- Volunteers
- 123 people
- Sponsor
- Assiut University
Atrial Fibrillation
Atrial Fibrillation in Turkey: Epidemiologic Registry-2
Atrial fibrillation (AF) is one of the most common cause of preventable ischemic stroke and associated with increased cardiovascular morbidity and mortality.
- Trial name
- AFTER-2 (NCT02354456)
- Where
- Turkey (Türkiye)
- Volunteers
- 4,100 people
- Sponsor
- Dicle University
Atrial Fibrillation, Stroke
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- NEW-AF (NCT03702582)
- Testing
- Rivaroxaban, Warfarin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Infertility
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
The purpose of this prospective observational cohort study is to evaluate the effect of routine clinical anticoagulant therapy on endometrial receptivity and subsequent pregnancy outcomes in women with infertility.
- Trial name
- NCT07494877
- Testing
- Routine Anticoagulant Therapy (Aspirin or Heparin Sodium)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tang-Du Hospital
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Atrial Fibrillation
Polish Atrial Fibrillation (POL-AF) Registry
Evaluation of clinical characteristics and pharmacotherapy of hospitalized Polish patients with atrial fibrillation (AF).
- Trial name
- POL-AF (NCT04419012)
- Testing
- observation
- Where
- Poland
- Volunteers
- 4,000 people
- Sponsor
- Jan Kochanowski University
Continuous Renal Replacement Therapy (CRRT)
Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)
This is a single-center, randomized, open-label, parallel-controlled clinical trial designed to investigate the anticoagulation efficacy and safety of different initial doses of Nafamostat Mesilate (NM) in ICU patients undergoing…
- Trial name
- NCT07469072
- Testing
- Nafamostat Low-Dose Group, Nafamostat High-Dose Group
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhujiang Hospital
Peripheral Arterial Disease(PAD)
Effect of Anticoagulant and Antiplatelet Drug Intervention on Postoperative Major Adverse Events in Patients with PAD：Phase II
This study is a multicenter, prospective, observational research project. It is anticipated to enroll a total of 6,000 patients between February 1, 2025, and January 31, 2028 (with completion of one-year postoperative follow-up…
- Trial name
- NCT06850207
- Volunteers
- 6,000 people
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Non Valvular Atrial Fibrillation (nv AF)
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
"The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOAC) and with anti vitamin K…
- Trial name
- Presage-Aco (NCT02906527)
- Testing
- Non-exposed group, Exposed group
- Volunteers
- 150,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Atrial Fibrillation
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention…
- Trial name
- FinACAF (NCT04645537)
- Volunteers
- 400,000 people
- Sponsor
- Helsinki University Central Hospital
Atrial Fibrillation (AF)
Gastroprotective Efficacy of Rebamipide in Patients With Atrial Fibrillation Treated With DOACs
The goal of this clinical trial is to learn if Rebamipide effective in gastroprotection in patients with atrial fibrillation who are treated with Direct Oral Anticoagulants (DOACs).
- Trial name
- REGATA (NCT07354230)
- Testing
- Rebamipide 100mg, Pantoprazole
- Where
- Russia
- Volunteers
- 210 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolism
Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials.
- Trial name
- NCT04736719
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 19,002 people
- Sponsor
- Brigham and Women's Hospital
Deep Vein Thrombosis
Residual Vein Thrombosis Establishes the Optimal Duration of Oral Anticoagulants
ABSTRACT Background The optimal duration of oral anticoagulant treatment in patients with idiopathic venous thromboembolism is still uncertain .
- Trial name
- DACUS (NCT00438230)
- Testing
- Warfarin
- Volunteers
- 250 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Venous Thromboembolism, Embolism and Thrombosis
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
- Conditions
- Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures
- Trial name
- NCT00119457
- Testing
- TTP889
- Where
- 21 sites in Czechia, Denmark and 2 more
- Volunteers
- 300 people
- Sponsor
- vTv Therapeutics
Intracardiac Thrombus, STEMI
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
Left ventricular thrombus is found in 10 to 25% of patients with impaired left ventricular function following ST-segment elevation myocardial infarction and up to 20% in dilated cardiomyopathy in observational studies.
- Conditions
- Intracardiac Thrombus, STEMI, Heart Failure
- Trial name
- ARGONAUT (NCT05825573)
- Testing
- Vitamin K antagonist, Direct oral anticoagulant
- Where
- 35 sites in France, Reunion
- Volunteers
- 340 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes